ArticleChemical & biomedical imaging2026
Endogenous Albumin-Mediated Disassembly of Phthalocyanine Nanoparticles for Tumor-Selective Imaging and Sonodynamic Therapy.
Article in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Counterion modulation of aza-BODIPY aggregation behaviour for boosted sonodynamic therapy.Chemical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albumin, the most abundant plasma protein, is a clinically significant biomarker that has been extensively utilized as an endogenous carrier for drug delivery due to its high binding affinity for hydrophobic ligands and its tendency to accumulate and be metabolized in tumors. Sonodynamic therapy (SDT) combines low-intensity ultrasound with sonosensitizers to produce cytotoxic reactive oxygen species, offering deep tissue penetration and spatiotemporal control that can complement or even surpass traditional photodynamic therapies. However, there is a need for straightforward, activatable platforms that link tumor-associated albumin recognition with selective SDT activation. In this study, we engineer an amphiphilic zinc-(II) phthalocyanine derivative that self-assembles into albumin-responsive nanoaggregates (NanoPcS). These aggregates exhibit quenched fluorescence and sonoactivity, which are activated upon binding to albumin and subsequent disassembly. This versatile design allows NanoPcS to serve as both an activatable probe and an effective SDT agent, enabling fluorescence reporting of albumin-rich tumor microenvironments while also generating ultrasound-triggered reactive oxygen species for cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.